此页面是自动翻译的,不保证翻译的准确性。请参阅 英文版 对于源文本。

User Performance and System Accuracy Evaluations Using Glucose Adjustment

2017年8月14日 更新者:LifeScan
This is an open-label, non-randomised pilot study, to evaluate user performance and system accuracy in blood Glucose monitoring system with glucose adjustment. Twelve male and female volunteers aged 18-45, with a documented diagnosis of Type I diabetes for at least 12 will be enrolled in this study.

研究概览

地位

完全的

研究类型

介入性

注册 (实际的)

12

阶段

  • 不适用

联系人和位置

本节提供了进行研究的人员的详细联系信息,以及有关进行该研究的地点的信息。

学习地点

    • Antrim
      • Belfast、Antrim、英国、BT2 7BA
        • BioKinetic Europe Ltd

参与标准

研究人员寻找符合特定描述的人,称为资格标准。这些标准的一些例子是一个人的一般健康状况或先前的治疗。

资格标准

适合学习的年龄

18年 至 45年 (成人)

接受健康志愿者

不

有资格学习的性别

全部

描述

Summary of inclusion criteria.

  • Male and female volunteers aged 18-45, with a documented diagnosis of Type I diabetes for at least 12 months and treated with a basal bolus insulin regime, and deemed otherwise healthy as determined by medical history, physical examination, laboratory test values, vital signs and 12-lead ECGs at screening.
  • Non-smokers from at least 12 months before study start and for the duration of the study.
  • Body mass index (BMI) ≥ 18 and ≤ 30 kg/m2.
  • Able to voluntarily provide written informed consent to participate in the study.
  • Must understand the purposes and risks of the study and agree to follow the restrictions and schedule of procedures as defined in the protocol, as confirmed during the informed consent process.
  • Must be willing to consent to have data entered into The Over Volunteering Prevention System (TOPS).
  • The volunteer's primary care physician has confirmed within the last 12 months that there is nothing in their medical history that would preclude their enrolment into a clinical study.
  • User Performance Accuracy Testing Only: Self-Monitoring - Volunteer is currently performing unassisted self-monitoring of blood glucose.

Summary of exclusion criteria.

  • A severe hypoglycaemic reaction, defined as causing loss of consciousness and/or requiring outside assistance with oral or intravenous glucose or a glucagon injection, within 7 days of the study start date.
  • Female volunteers who are pregnant or lactating.
  • Positive for human immunodeficiency virus (HIV), hepatitis B or hepatitis C.
  • Current or history of drug or alcohol abuse or a positive drugs of abuse or alcohol test at screening or check-in.
  • Participation in a clinical drug study during the 90 days prior to study start.
  • Any clinically significant illness within 30 days prior to study start.
  • Donation of blood or blood products within 30 days prior to study start, or at any time during the study, except as required by this protocol.
  • Weekly alcohol intake exceeding the equivalent of 14 units per week for females or 21 units per week for males.
  • Consumption of alcoholic beverages within 48 hours prior to check-in.
  • Volunteers with a substantial change in eating habits within 30 days prior to study start or volunteers who cannot comply with the standardised meals proposed for use in the study.
  • Prior experience with the BGMSs used for the study.
  • Volunteers who are currently working for, have previously worked for, or have an immediate family member working for a company that manufactures or markets blood glucose monitoring products.
  • Volunteers who have laboratory training or experience (medical technologist, laboratory technician, laboratory assistant etc).
  • Volunteers who, in the opinion of the Investigator, are unsuitable for participation in the study.

学习计划

本节提供研究计划的详细信息,包括研究的设计方式和研究的衡量标准。

研究是如何设计的?

设计细节

  • 主要用途:其他
  • 分配:不适用
  • 介入模型:单组作业
  • 屏蔽:无(打开标签)

武器和干预

参与者组/臂
干预/治疗
实验性的:血糖监测系统(BGMS)
干预:血糖监测系统 (BGMS) 从 BGMS 获得的 UP 和 SA 结果与参考仪器 (YSI) 进行比较
In vitro diagnostic medical device.

研究衡量的是什么?

主要结果指标

结果测量
措施说明
大体时间
User Performance (UP) evaluation.
大体时间:Up to 6 hours
UP evaluation of blood glucose monitoring systems compared to a reference instrument. Samples collected by subject and HCP
Up to 6 hours
System Accuracy (SA) evaluation
大体时间:Up to 6 hours
UP evaluation of blood glucose monitoring systems compared to a reference instrument. Samples collected by HCP only.
Up to 6 hours

合作者和调查者

在这里您可以找到参与这项研究的人员和组织。

赞助

调查人员

  • 首席研究员:David J Bell、BioKinetic Europe Ltd

研究记录日期

这些日期跟踪向 ClinicalTrials.gov 提交研究记录和摘要结果的进度。研究记录和报告的结果由国家医学图书馆 (NLM) 审查,以确保它们在发布到公共网站之前符合特定的质量控制标准。

研究主要日期

学习开始 (实际的)

2015年2月1日

初级完成 (实际的)

2015年2月1日

研究完成 (实际的)

2015年2月1日

研究注册日期

首次提交

2015年2月18日

首先提交符合 QC 标准的

2015年2月24日

首次发布 (估计)

2015年3月2日

研究记录更新

最后更新发布 (实际的)

2017年8月16日

上次提交的符合 QC 标准的更新

2017年8月14日

最后验证

2017年8月1日

更多信息

与本研究相关的术语

药物和器械信息、研究文件

研究美国 FDA 监管的药品

不

研究美国 FDA 监管的设备产品

不

在美国制造并从美国出口的产品

不

此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.

订阅